Sanofi: New 48-Week Frexalimab Phase 2 Data Support Potential for High Sustained Efficacy in Multiple Sclerosis
April 18, 2024
April 18, 2024
PARIS, France, April 18 -- Sanofi, a life sciences company, issued the following news release on April 17, 2024:
Sanofi's CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis. These data will be presented today at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, Colorado, US. Results from the 12-week double-blind study period were . . .
Sanofi's CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis. These data will be presented today at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, Colorado, US. Results from the 12-week double-blind study period were . . .